Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
Go back to Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)| BANCO SANTANDER S.A. (NYSE: SAN) | Delayed: 14.31 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.31 | 52 Week High | $5.58 | |||
| Open | $14.31 | 52 Week Low | $3.60 | |||
| Day High | $14.31 | P/E | N/A | |||
| Day Low | $14.31 | EPS | $0.00 | |||
| Volume | 35,728 | |||||
| SANOFI (NASDAQ: SNY) | Delayed: 42.48 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $42.48 | 52 Week High | $44.76 | |||
| Open | $42.48 | 52 Week Low | $36.81 | |||
| Day High | $42.48 | P/E | N/A | |||
| Day Low | $42.48 | EPS | $0.00 | |||
| Volume | 9,954 | |||||
